126 related articles for article (PubMed ID: 8822090)
1. Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells.
Ikegami Y; Yano S; Nakao K
Jpn J Pharmacol; 1996 Jan; 70(1):65-72. PubMed ID: 8822090
[TBL] [Abstract][Full Text] [Related]
2. Effects of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells.
Ikegami Y; Yano S; Nakao K
Arzneimittelforschung; 1996 Feb; 46(2):201-4. PubMed ID: 8720314
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on murine and human tumor models.
Ikegami Y; Yano S; Nakao K; Fujita F; Fujita M; Sakamoto Y; Murata N; Isowa K
Arzneimittelforschung; 1995 Nov; 45(11):1225-30. PubMed ID: 8929245
[TBL] [Abstract][Full Text] [Related]
6. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells.
Courage C; Snowden R; Gescher A
Br J Cancer; 1996 Oct; 74(8):1199-205. PubMed ID: 8883405
[TBL] [Abstract][Full Text] [Related]
8. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells.
Akinaga S; Nomura K; Gomi K; Okabe M
Cancer Chemother Pharmacol; 1994; 33(4):273-80. PubMed ID: 7506638
[TBL] [Abstract][Full Text] [Related]
9. Analogs of staurosporine: potential anticancer drugs?
Gescher A
Gen Pharmacol; 1998 Nov; 31(5):721-8. PubMed ID: 9809468
[TBL] [Abstract][Full Text] [Related]
10. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
Zaugg K; Rocha S; Resch H; Hegyi I; Oehler C; Glanzmann C; Fabbro D; Bodis S; Pruschy M
Cancer Res; 2001 Jan; 61(2):732-8. PubMed ID: 11212276
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
Nishio K; Ishida T; Arioka H; Kurokawa H; Fukuoka K; Nomoto T; Fukumoto H; Yokote H; Saijo N
Anticancer Res; 1996; 16(6B):3387-95. PubMed ID: 9042196
[TBL] [Abstract][Full Text] [Related]
12. Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production.
Si MS; Reitz BA; Borie DC
Int Immunopharmacol; 2005 Jul; 5(7-8):1141-9. PubMed ID: 15914319
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer.
Xue Y; Ren H; Xiao W; Chu Z; Lee JJ; Mao L
Int J Oncol; 2012 Nov; 41(5):1798-808. PubMed ID: 22948297
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells.
Hemström TH; Sandström M; Zhivotovsky B
Int J Cancer; 2006 Sep; 119(5):1028-38. PubMed ID: 16570272
[TBL] [Abstract][Full Text] [Related]
15. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.
Thavasu P; Propper D; McDonald A; Dobbs N; Ganesan T; Talbot D; Braybrook J; Caponigro F; Hutchison C; Twelves C; Man A; Fabbro D; Harris A; Balkwill F
Cancer Res; 1999 Aug; 59(16):3980-4. PubMed ID: 10463595
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C.
Akinaga S; Nomura K; Gomi K; Okabe M
Cancer Chemother Pharmacol; 1993; 32(3):183-9. PubMed ID: 8500222
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.
Courage C; Budworth J; Gescher A
Br J Cancer; 1995 Apr; 71(4):697-704. PubMed ID: 7710931
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine.
Courage C; Bradder SM; Jones T; Schultze-Mosgau MH; Gescher A
Int J Cancer; 1997 Nov; 73(5):763-8. PubMed ID: 9398059
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of acriflavine in lung adenocarcinoma cell line A549.
Lee CJ; Yue CH; Lin YJ; Lin YY; Kao SH; Liu JY; Chen YH
Anticancer Res; 2014 Nov; 34(11):6467-72. PubMed ID: 25368247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
